Featured Proteomics & Sequencing Preparations
Bridging Genomics and Proteomics for Global Research
Biomarker Technologies (BMKGene), established in 2009, is a pioneer in multi-omics solutions. Over the past 16 years, we have continuously pushed the boundaries of high-throughput sequencing, bioinformatics, and mass spectrometry-based proteomics. Underpinning our technical dominance are more than 60 national invention patents and over 200 software copyrights.
Our academic cooperation framework is designed to lower the barrier to entry for complex translational research. By integrating mass spectrometry-based proteomics with genomics, metagenomics, single-cell transcriptomics, and spatial biology, we offer researchers a holistic view of biological systems. Through global collaborations spanning 84 regions, we enable institutions to translate raw molecular data into high-impact publications and biological insights.
Proteins are the functional executioners of the genome. While genomics indicates what *might* happen, proteomics reveals what is *actually* occurring in the cell. Our mass spectrometry workflows allow quantitative, deep-dive profiling of proteomes to identify biomarkers, map signaling networks, and validate genomic predictions.
Industrial & Commercial Landscape of Proteomics
The global mass spectrometry-based proteomics market is experiencing exponential growth, driven by key advancements in instrumentation sensitivity, throughput, and analytical software. In the industrial sector, proteomics has transitioned from a basic discovery tool to a core pillar of clinical trials, target identification, and biopharmaceutical development.
1. High-Throughput Clinical Proteomics
Historically, mass spectrometry was limited by slow throughput and batch-to-batch variation. Today, commercial pipelines utilize Data-Independent Acquisition (DIA) and Tandem Mass Tagging (TMT) to profile thousands of proteomes per week. This scalability makes proteomics vital for cohort-scale clinical trials, where molecular profiling of patient plasma or tissue biopsy samples helps stratify patient groups and predict therapeutic responses.
2. Single-Cell & Spatial Proteomics
The frontier of biology lies in understanding cellular heterogeneity. While spatial transcriptomics (such as our proprietary BMKMANU S3000) maps gene expression, spatial proteomics maps the actual protein expression and post-translational modifications (PTMs) in tissue microenvironments. This is essential for studying the tumor microenvironment, where the spatial localization of immune checkpoints determines immunotherapy success.
3. AI-Driven Proteomics and Bioinformatics
With the explosion of mass spectrometry data, artificial intelligence and deep learning models are now used to predict peptide fragmentation patterns, retention times, and protein-protein interactions. BMKGene’s self-developed BMKCloud bioinformatics platform leverages massive computing power to process raw mass spectra, providing researchers with annotated biological pathways, regulatory network analyses, and multi-omics integration.
Mass Spectrometry Proteomics: Deep Application Scenarios
From agricultural crop optimization to clinical biomarker discovery, mass spectrometry provides unparalleled molecular resolution. Below are the primary application scenarios where BMKGene collaborates with academic and industrial entities.
Clinical Biomarkers
Identifying early diagnostic markers for cancer, neurodegenerative diseases, and cardiovascular conditions. By analyzing cerebrospinal fluid, plasma, or urine via high-resolution QTOF and QTRAP platforms, we pinpoint low-abundance disease-related proteins.
Agricultural Proteomics
Optimizing crop resistance and yield. Academic partners utilize proteomics to study how plants respond to drought, salinity, and pathogens at the protein level, working in tandem with comparative genomics and soil metagenomics.
PTM Profiling
Investigating phosphorylation, ubiquitination, and glycosylation. Post-translational modifications dictate protein activity and cellular signaling. High-resolution mass spectrometry is the only definitive method to map these dynamic states.
By combining our DNA extraction kits (e.g., TGuide Smart Soil / Stool DNA Kit) with downstream metaproteomics, researchers can analyze not only which microbes are present in a soil or gut sample, but also which metabolic pathways and enzymes are actively expressed. This is a critical workflow for environmental sustainability and microbiome-host interaction studies.
Leading Multi-level High-throughput Sequencing & Proteomics Platforms
BMKGene operates state-of-the-art molecular biology and mass spectrometry facilities, maintaining strict SOPs to ensure reproducibility and data accuracy.
Advanced Instrumentation
PacBio platforms: Sequel II, Sequel, RSII
Nanopore platforms: PromethION P48, GridION X5, MinION
10X Genomics: 10X ChromiumX, 10X Chromium Controller
Illumina platforms: NovaSeq
BGI-sequencing platforms: DNBSEQ-G400, DNBSEQ-T7
Physical Mapping: Bionano Irys system
Mass Spectrometry: Waters XEVO G2-XS QTOF, QTRAP 6500+
20,000+ Sq. Ft. Clean Rooms
Our facility houses advanced biomolecular laboratory instruments. Standardized laboratories are divided into dedicated zones for sample extraction, library construction, clean rooms, and sequencing. Strict SOPs govern the transition of samples from extraction to final data delivery.
BMKCloud Bioinformatics
Our self-developed cloud platform provides academic collaborators with massive computational resources: CPUs with 41,104 memory, 3 PB total storage, and 4,260 computing cores delivering peak computing power over 121,708.8 Gflop per second.
Next-Gen Automation: Brilliant Lab 1000
Brilliant Lab 1000 (BL1000) Joint Venture
Biomarker Technologies (BMKGENE) and PerkinElmer have jointly built a fully automated experimental production line, called Brilliant Lab 1000 (BL1000). This state-of-the-art system is applied directly to high-throughput NGS library construction and sample preparations.
By automating liquid handling, plate transfers, and quality control steps, BMKGENE drastically improves throughput, minimizes human error, and shortens project delivery cycles. This ensures that large-scale academic cohorts receive consistent, high-quality multi-omics data.
Enterprise Qualifications & Global Certifications
Our commitment to scientific excellence is validated by international standards, national patents, and collaborative academic workstations. We maintain rigorous compliance across all experimental and data analysis workflows.
Patents & ISO Standardizations
![[Copy] Eukaryotic mRNA Sequencing-NGS](http://www.bmkgene.com/uploads/%E7%BD%91%E7%AB%99%E4%BA%A7%E5%93%8125.1.14-033.jpg)
